Patient-Reported Outcome Measures for Post-mastectomy Breast Reconstruction: A Systematic Review of Development and Measurement Properties

C. F. Davies, BSc (Hons) PhD, R. Macefield, MSc, K. Avery, PhD, J. M. Blazeby, MD, and S. Potter, PhD

1Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Bristol, UK; 2University Hospitals Bristol Foundation NHS Trust, Bristol, UK; 3Bristol Breast Care Centre, North Bristol NHS Trust, Bristol, UK

ABSTRACT

Background. Breast reconstruction (BR) is performed to improve outcomes for patients undergoing mastectomy. A recently developed core outcome set for BR includes six patient-reported outcomes that should be measured and reported in all future studies. It is vital that any instrument used to measure these outcomes as part of a core measurement set be robustly developed and validated so data are reliable and accurate. The aim of this systematic review is to evaluate the development and measurement properties of existing BR patient-reported outcome measures (PROMs) to inform instrument selection for future studies.

Methods. A PRISMA-compliant systematic review of development and validation studies of BR PROMs was conducted to assess their measurement properties. PROMs with adequate content validity were assessed using three steps: (1) the methodological quality of each identified study was assessed using the COSMIN Risk of Bias checklist; (2) criteria were applied for assessing good measurement properties; and (3) evidence was summarized and the quality of evidence assessed using a modified GRADE approach.

Results. Fourteen articles reported the development and measurement properties of six PROMs. Of these, only three (BREAST-Q, BRECON-31, and EORTC QLQ-BRECON-23) were considered to have adequate content validity and proceeded to full evaluation. This showed that all three PROMs had been robustly developed and validated and demonstrated adequate quality.

Conclusions. BREAST-Q, BRECON-31, and EORTC QLQ-BRECON-23 have been well-developed and demonstrate adequate measurement properties. Work with key stakeholders is now needed to generate consensus regarding which PROM should be recommended for inclusion in a core measurement set.

Breast cancer is the most common cancer in women, with over 2 million new cases worldwide in 2018.1 In the UK, approximately 40% of women who have surgery for breast cancer undergo mastectomy.2 Breast reconstruction is offered to patients to improve body image and quality of life.3

Decision-making for BR is complex. There are many types of BR surgery ranging from implant-based procedures to microsurgical free-flaps using tissue from the abdomen, thigh, or buttock. Patients and surgeons need high-quality evidence from well-designed studies to help them make informed decisions about their reconstructive options.

Outcome selection, measurement, and reporting in BR studies, however, is currently heterogeneous and inconsistent.4,5 This means that results of individual studies cannot be meaningfully compared or combined, limiting their value for decision-making. To address this, a core outcome set (COS), a minimum set of outcomes to be measured and reported in all future research and audit studies of BR, has recently been developed. Robust Delphi methodology involving over 300 key stakeholders, including patients and healthcare professionals, was undertaken.6 The 11-item COS includes clinical (implant
and flap-based complications, major complications, and unplanned surgery), patient-reported (quality of life, normality, emotional and physical well-being, donor-site symptoms/morbidity, and self-esteem), and cosmetic (women’s cosmetic satisfaction) outcome domains.

While a COS is an important step in determining what outcomes should routinely be measured, this does not describe how these key outcome domains should be assessed. The next step in improving the quality and consistency of outcome reporting in BR studies is therefore to develop a core measurement set (CMS), a standard set of instruments to assess the core outcome domains. Patient-reported outcomes are particularly important in BR, and it is vital that any patient-reported outcome measure (PROM) recommended for use in future studies be robustly developed and validated for use in this population. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guideline is a critical appraisal tool for evaluating the methodological quality of studies reporting the development and measurement properties of health-related measures. This provides a framework to assess the overall quality of outcome measurement instruments for use in research and clinical practice. The aims of this systematic review are to (1) identify candidate PROMs for each patient-reported outcome domain in the BR COS and (2) to critically appraise, compare, and summarize the quality of studies reporting the development and measurement properties of each PROM using the COSMIN guidelines to inform selection of PROMs for use in future BR studies and inclusion in a BR CMS.

**METHODS**

This study was registered on the PROSPERO international register of systematic reviews before the literature search was performed (CRD42017075211).

**Search Strategy and Paper Identification**

A systematic search strategy was applied to the OVID versions of MEDLINE (1946–February 2019), EMBASE (1974–February 2019), and PsycINFO (1806–February 2019) to identify articles reporting the development and measurement properties of PROMs developed for and/or validated in women undergoing BR surgery. The search was limited to human studies published in English from database inception up to and including the 26 February 2019. Abstracts and conference reports were excluded due to difficulties evaluating incomplete information. Reference lists of included articles were hand searched for further relevant publications. Duplicate records were excluded.

The search strategy used four broad search terms recommended by COSMIN for performing a systematic review of measurement properties: These were: (1) the constructs of interest, namely the patient-reported outcome domains included in the BR COS (self-esteem, normality, quality of life, donor-site problems, emotional and physical well-being, and women’s cosmetic satisfaction), (2) the target population (BR), (3) the comprehensive PROM filter developed by the Patient Reported Outcomes Measurement Group of the University of Oxford, and (4) the measurement properties filter described by Terwee et al. The full search strategy is detailed in “Appendix”.

Initial scoping work suggested that few PROMs currently exist that have been developed and/or validated specifically for patients undergoing BR surgery. For this reason, no specific construct for BR were included in the search strategy to avoid suitable instruments being inappropriately excluded.

Titles and abstracts of the remaining citations were screened independently for eligibility by two reviewers (C.D./S.P.) using predetermined inclusion criteria. Any discrepancies were resolved by discussion between the two reviewers. If uncertainty remained, the full text was obtained for further review and discussion. The reference lists of retrieved articles and existing reviews were manually searched to identify additional potentially relevant studies.

**Paper Selection**

Full-text original papers published in English reporting the development and/or evaluation of the measurement properties of patient-reported outcome questionnaires in women undergoing BR were eligible for inclusion. Further eligibility criteria included that the questionnaire had to have been developed for patient self-completion, evaluate one of the core patient-reported outcome domains identified in the COS (i.e., health-related quality of life, normality; women’s cosmetic satisfaction; physical well-being, emotional well-being, or self-esteem) to be relevant for inclusion in the CMS, and have been specifically developed for and/or evaluated in female patients aged 18 years or over who had undergone BR. Breast reconstruction was defined as reconstruction of the breast after total mastectomy for invasive or preinvasive breast cancer or risk reduction.

Excluded were studies involving patients (1) with breast cancer in general without specific reference to BR, (2) undergoing breast conserving surgery or partial BR [e.g., with latissimus dorsi (LD) miniflaps or chest wall...
perforator flaps], and (3) undergoing cosmetic breast surgery only (e.g., reduction or augmentation surgery).

Papers were screened for inclusion independently by two reviewers (S.P./C.D.) using standardized proforma based on predetermined inclusion criteria. In cases of uncertainty, full-text papers were obtained for further evaluation. Uncertainties that remained after full-text review were resolved by discussion with an experienced methodologist (K.A./R.M.). Reasons for exclusion were recorded.

Data Extraction

Data were extracted onto standardized data extraction proforms. Extracted data included (1) characteristics of PROM instruments, including name of instrument, purpose/objective of study, country of study, recall period, and measurement properties evaluated, (2) PROM instruments assessing each patient-reported outcome domain from the BR COS, including COS item definition, name of PROM instrument, outcome/scales being measured, and number of items per scale, and (3) characteristics of included studies of instruments assessing outcomes in women who had undergone BR, including study author/year, country of study/setting, instrument name, sample size, age (mean), target population, type of RBS performed, and the indication for surgery.

Data Analysis

Selection of PROM Instruments for Full COSMIN Evaluation Nine measurement properties are included in the COSMIN evaluation.11 These included content, structural, cross-cultural and criterion validity, hypothesis testing for construct validity, internal consistency, reliability, measurement error, and responsiveness. Definitions of these properties are provided in Table 1.

Content validity is the most important measurement property of a PROM and refers to whether the content of an instrument appropriately reflects the construct to be measured. It must be clear that items in the PROM are relevant, comprehensive, and comprehensible with respect to the construct of interest and the target population.15 Only PROMs assessed by COSMIN criteria as having adequate content validity qualified for full COSMIN evaluation in phase 2 (Fig. 1). PROMs assessed as lacking content validity were excluded from further evaluation (Fig. 1, phase 1).11,15,16

For PROM instruments undergoing full COSMIN evaluation, data on the instrument’s feasibility were also collected. These included patient comprehensibility, completion time, patient’s required mental and physical ability level, ease of standardization, ease of score calculation, copyright, cost of using instrument, required equipment, and regulatory agency’s requirement for approval.

Evaluating Quality of the PROMs Quality evaluation of the included PROMs consisted of three steps (Fig. 1) and was scored by three reviewers (C.D./R.M./K.A.) independently with disagreements resolved by discussion with a fourth (S.P.).

Step 1. COSMIN Risk of Bias Checklist To evaluate the methodological quality of each single study, the COSMIN Risk of Bias checklist10,11,17 was used. The COSMIN checklist evaluates the nine measurement properties together with the feasibility and interpretability of the instrument. The risk of bias for each study was rated using a four-point scale as either very good, adequate, doubtful, or inadequate quality and determined by taking the lowest rating of any items (“worst score counts”) within each measurement property.

Step 2. Applying Criteria for Good Measurement Properties by Using Quality Criteria 2a: Content Validity Each result of a single study on PROM development and content validity was rated against the 10 criteria for good content validity.17 The results of all available studies were qualitatively summarized to determine whether, overall, the relevance, comprehensiveness, comprehensibility, and overall content validity was sufficient (+), insufficient (−), or indeterminate (?), taking all evidence into account. Studies assessed as having insufficient content validity following this assessment were excluded from further evaluation in the systematic review as these should not be recommended for use.

2b: Remaining Measurement Properties For instruments assessed as having sufficient content validity, the result of each study for the remaining measurement properties were rated against the criteria for good measurement properties.11 Each result was rated as either sufficient (+), insufficient (−), or indeterminate (?).

Step 3. Summary of Evidence and Grading of Quality of Evidence 3a: Content Validity The overall ratings determined in step 2a were also accompanied by a grading for the quality of the evidence using a modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for systematic reviews of clinical trials18 (scored as high, moderate, low, or very low). The GRADE approach uses five factors to determine the quality
of the evidence: risk of bias, inconsistency, indirectness, imprecision, and publication bias. For evaluating content validity, only three of these factors were applicable, namely risk of bias, inconsistency, and indirectness.

3b: Remaining Measurement Properties To come to an overall conclusion on the quality of a PROM, the results of all available studies per measurement property had to be consistent. The results were pooled and compared against the criteria for good measurement properties\textsuperscript{11} to determine whether, overall, the measurement property of the PROM was sufficient (+), insufficient (−), inconsistent (±), or indeterminate (?). As with content validity, quality of the evidence was graded using the GRADE approach for each measurement property. For evaluating measurement properties in systematic review of PROMs, only four of the five factors (as detailed in step 3a above) were taken into

| Measurement property                  | Definition                                                                 |
|--------------------------------------|---------------------------------------------------------------------------|
| Internal consistency                 | The degree of the interrelatedness among the items; the extent to which scores for patients who have not changed are the same using different sets of items from same instrument |
| Reliability                          | The proportion of the total variance in the measurements which is due to “true” differences between patients |
| Measurement error                    | The systematic and random error of a patient’s score that is not attributed to true changes in the construct to be measured |
| Content validity                     | The degree to which an instrument measures the construct(s) it purports to measure; the degree to which the content of an instrument is an adequate reflection of the construct to be measured |
| Structural validity                  | The degree to which the scores of an instrument are an adequate reflection of the dimensionality of the construct to be measured |
| Hypothesis testing for construct validity | The degree to which the scores of an instrument are consistent with hypotheses (for instance, with regard to internal relationships, relationships to scores of other instruments, or differences between relevant groups) based on the assumption that the instrument validly measures the construct to be measured; item construct validity |
| Cross-cultural validity              | The degree to which the performance of the items on a translated or culturally adapted instrument are an adequate reflection of the performance of the items of the original version of the instrument |
| Criterion validity                   | The degree to which the scores of an instrument are an adequate reflection of a “gold standard” |
| Responsiveness                       | The ability of an instrument to detect change over time in the construct to be measured; item responsiveness |

Definitions as described in COSMIN guidelines manual V1.0, 2018\textsuperscript{15}
account, namely risk of bias, inconsistency, imprecision, and indirectness.

RESULTS

Systematic Literature Search

After removal of duplicates, 2343 abstracts were screened. For full-text review based on the title and abstract, 27 articles were selected. Of these, 16 articles were excluded from the review for the following reasons: not primary research/reviews (n = 8), not validation studies (n = 5), or not related to BR surgery (n = 3). A further three papers were identified from manual searching. 14 articles describing six BR PROMs met the eligibility criteria and were included in the review (see PRISMA diagram, Fig. 2).

Characteristics of Included PROMs

Table 2 presents the characteristics of the BR PROMs identified in the review. All included PROMs were evaluated in the English language. The recall period ranged from “within the last week” to “5 years since breast surgery.” Individual studies evaluated different measurement properties and not all measurement properties were assessed for each PROM. A list of which specific measurement properties were measured per instrument is presented in Table 2.

Assessment of Breast Reconstruction Patient-Reported Outcome Domains

Outcome domains or constructs measured across the identified PROMs included satisfaction with breasts, satisfaction with overall outcome, psychosocial well-being,
| PROM/instrument (references) | Purpose/objective of study | Country (language in which the questionnaire was evaluated) | Type of admin/recall period | Constructs and subscales measured (no. of items) | COSMIN measurement properties evaluated |
|-------------------------------|----------------------------|-------------------------------------------------------------|-----------------------------|-------------------------------------------------|--------------------------------------|
| BREAST Q (Pusic et al.19)     | To develop a new patient-reported outcome measure to assess the unique outcome of breast surgery patients | USA and Canada | To comment on their satisfaction or aspects of HRQoL during the previous 2 weeks | Constructs: Satisfaction and HRQoL. Three HRQoL domains: physical, psychosocial, and sexual wellbeing. Three satisfaction domains: breasts, outcome, and care (163 items) | Structural validity Acceptability Reliability-internal consistency Test-retest reproducibility Content validity Construct validity (hypothesis testing) Scale validity Reliability-internal consistency and test-retest reliability Scale reliability Content validity Structural validity Construct validity (hypothesis testing) Clinical validity |
| BREAST Q (Cano et al.20)      | To independently validate BREAST Q and focus on the clinical interpretability of the instruments scores | USA and Canada | To comment on their satisfaction or aspects of HRQoL during the previous 2 weeks | Constructs: Breast reduction, augmentation, reconstruction, and mastectomy w/o reconstruction Six domains: satisfaction with breasts, satisfaction with overall outcome, psychosocial well-being, sexual well-being, physical well-being, satisfaction with care | |
| BREAST Q (Browne et al.21)    | To develop two new measurement scales specifically for LD reconstruction patients to evaluate the aesthetic and functional outcomes of LD flap BR and assess their psychometric properties | UK | Outcomes were measured 18 months after surgery | Back appearance scale (8 items) Back and shoulder function scale (11 items) | Structural validity Internal consistency (also measured person separation index) |
| BREAST Q CAT (Young-Afat et al.21) | To develop a computerized adaptive test (CAT) to shorten the BREAST Q’s satisfaction with breasts scale | USA | | Constructs: Satisfaction with breasts scale only (of the reconstruction module) Satisfaction with breasts (10-16 items) | Internal consistency |
| Electronic version of BREAST Q (Puzesi et al.25) | To evaluate the psychometric properties of an electronic version of the BREAST Q in a large online survey | USA | | Constructs: QoL, satisfaction, and patient experience (17 items) | Acceptability Reliability (scale) Content validity Construct validity (hypothesis testing) Convergent validity Clinical validity Discriminant validity |
| BRECON (Temple et al.27)      | To develop a valid, reliable, and responsive self-admin questionnaire to assess women’s satisfaction with BR | Canada | Average time from surgery to participation was 2.9 years | Constructs: HRQoL and satisfaction (100 items in total) | Content validity (a 100-item pilot questionnaire was developed for further psychometric testing) |
| BRECON 31 (Temple-Oberle et al.25) | To develop a reliable and valid questionnaire to assess patient satisfaction with BR | Canada | Feelings regarding BR within past 2 weeks | Constructs: HRQoL and satisfaction Self-image, arm concerns, intimacy, satisfaction, recovery, self-consciousness, expectations, appearance, nipple, abdomen (31 items) (with additional two subscales where applicable: 4 items for nipple recon and 10 items for abdominal donor site) | Internal consistency Reliability Construct validity Content validity Face validity Criterion validity |
| BRECON 31 (Temple-Oberle et al.26) | To verify the subscale structure of the BRECON 31 using a test sample of women naive to the questionnaire | Canada | Feelings regarding BR within past 2 weeks | Constructs: HRQoL and satisfaction Self-image, arm concerns, intimacy, satisfaction, recovery, self-consciousness, expectations, appearance, nipple, abdomen (31 items) (with two additional subscales | Internal consistency Reliability Content validity Face validity |
| PROM/instrument (references) | Purpose/objective of study | Country (language in which the questionnaire was evaluated) | Type of admin/recall period | Constructs and subscales measured (no. of items) | COSMIN measurement properties evaluated |
|------------------------------|-----------------------------|---------------------------------------------------------------|----------------------------|-------------------------------------------------|----------------------------------------|
| EORTC QLQ BRECON (Thomson et al.25) | To develop and validate the first European multicultural BR specific pre- and post-op PROM | English, Italian, and Swedish translations | 3 years since BR (range 1–8 years) | Treatment or surgery related items Body image Sexuality Cosmetic outcome Overall satisfaction (Provisional module: 5 domains and 31 items) | A 31-item pilot questionnaire was developed for psychometric testing |
| EORTC QLQ-BRECON (BRR) 26 (Winters et al.26) | To carry out phase three pretesting of the provisional 31 item EORTC QLQ-BRR questionnaire and assess the relevance, acceptability, and redundancy of Qu/Items | English, German, Italian, Swedish, Dutch, and French translations | 1–5 years after BR | Provisional three scales (HRQoL): Disease treatment/surgery related symptoms Sexuality Cosmetic outcome (provisional scales were reduced from 31 to 26 items) | Phase III pretesting aimed to assess comprehensibility and comprehensiveness Structural validity Internal consistency Construct validity- convergent validity Discriminant validity |
| EORTC QLQ-BRECON 23 (Winters et al.27) | To carry out phase IV international field-testing of the EORTC BRECON module to finalize scale structure and psychometric testing | International | Standard recall period: the past week | Constructs: HRQoL before and after BR Six subscales: Surgery side-effects, sexuality, satisfaction breast cosmetic, satisfaction nipple cosmetic, satisfaction with surgery, donor site symptoms + single item questions (15 items before mastectomy and BR and 9 items after BR) | Internal consistency Reliability Content validity Structural validity Construct validity (hypothesis testing) Convergent validity Discriminant validity Responsiveness Acceptability Interpretability Acceptability Internal consistency Reliability Interrater reliability Acceptability Internal consistency Reliability Interrater reliability Responsiveness Validity (comparison with other measures) |
| MBROS-S (Alderman et al.28) | To evaluate the effects of reconstructive technique, procedure timing, and age on esthetic and general satisfaction in women undergoing BR | USA and Canada | 1 year after completion of BR | Constructs: HRQoL and satisfaction with breasts Two scales measuring general satisfaction (five items) and esthetic satisfaction (seven items) | Internal consistency Reliability Interrater reliability |
| MBROS-BI (Wilkins et al.29) | To evaluate and compare psychosocial outcomes for three common options for mastectomy BR | USA and Canada | Previous 4 weeks | Constructs: HRQoL, and body image and sexual functioning HRQoL: social support and concerns about cancer reoccurrence Body image: appearance in clothes and bathing suit and naked, self-consciousness around others, physical attractiveness, satisfaction with body, self-confidence, self-esteem, and self-consciousness during sexual activity (nine items) | Acceptability Internal consistency Reliability Interrater reliability |
| Patient-based subjective rating scale for BR appearance (Cohen et al.30) | To develop a new instrument for assessing the appearance of autologous BR and compare patient and physician evaluations | USA | Undergone autologous BR at least 6 months previously | Positioning, defects in the breast, the breasts projection, the breast shape, quality of the inframammary fold, quality of the medial contour and overall appearance of breast, and overall satisfaction with BR | Internal consistency Reliability (intraobserver and interobserver) Test–retest reliability |
physical well-being, sexual well-being, health-related quality of life, body image, and sexual functioning. These constructs reflected most of the patient-reported outcome domains in the COS. Two COS constructs, namely normality and self-esteem, were not represented as multiitem domains in the identified PROMs. Several questionnaires, however, included single items relating to each of these constructs. For example, the construct of normality was measured in three PROMs (BREAST-Q, MBROS-BI, and BRECON-31), each of which contained individual items referring to “feeling normal.” For the self-esteem construct, the BREAST-Q included four items in the psychosocial well-being subscale addressing this issue. BRECON-31 included four items addressing self-image and three items relating to feeling self-conscious. Details of domains and PROMs are presented in Table 3.

Characteristics of Included Studies from Systematic PROMs Review

Table 4 presents the characteristics of the 14 studies included in the review. Studies were largely conducted in North America and/or Canada (n = 10), with only three studies based in Europe. One study recruited patients from 28 international centers. The sample sizes ranged from 20 to 5000 women with an age range of 18–84 years and included patients undergoing a range of implant-based and autologous reconstruction, including pedicled and free transverse rectus musculocutaneous (TRAM) flaps and latissimus dorsi reconstruction with and without implants; also, patients undergoing bilateral and unilateral surgery and patients receiving nipple/areola reconstruction as well as nipple-sparing procedures.

PROM Instruments Selection for Full COSMIN Evaluation

Of the six identified PROM instruments, only three, BREAST-Q,19–21 BRECON-31,22–24 and EORTC QLQ-BRECON 23,25–27 were considered to have adequate content validity (see below). Of the remainder, the Michigan BR Outcome Study (MBROS) group developed a BR-specific questionnaire item set for satisfaction (MBROS-S)28 and body image (MBROS-BI),29 using input from an expert panel alone. There was no direct patient input into item generation or reduction, therefore these questionnaires were considered to have insufficient content validity and were excluded from further COSMIN evaluation. Similarly, the patient-based subjective rating scale for BR appearance30 did not assess content validity and was excluded. Finally, the BREAST-Q CAT31 and the electronic BREAST-Q32 were adapted versions of the main BREAST-Q questionnaire. As the main BREAST-Q was being assessed, these were excluded.

Overall Rating and Grading of Quality of Evidence per Measurement Property for Each PROM

A summary of the analysis and grading of measurement properties for each of the three PROM instruments included for full COSMIN evaluation is presented in Table 5. This includes the summary of pooled results (from each study per PROM), the overall rating, and the grading of the quality of evidence assigned to each of the measurement properties that were measured. The overall ratings and quality of evidence for each measurement property assessed for the three PROMs are presented in a simpler way in Table 6 for ease of comparison between instruments. Cross-cultural validity, measurement invariance, and measurement error were not assessed for any of the three included PROMs and thus are not included in Table 6.

Content Validity

All three included PROMs, BREAST-Q, BRECON-31, and EORTC QLQ-BRECON 23, exhibited sufficient high-quality evidence for the three aspects of content validity (relevance, comprehensiveness, and comprehensibility) as well as the quality of the PROM development, with all three PROMs using extensive input from patients undergoing BR in item formation and from systematic reviews. The development and design of the BREAST-Q questionnaire was extensive, with interviews and focus groups of representative BR patients, and included feedback from healthcare professionals on its relevance and comprehensiveness.

The BRECON-31 used robust item generation and item reduction methods. Item generation was gained from patient focus groups with additional input from an expert panel (plastic surgeons, breast surgeons, and advanced practice nurses) and a literature review. The literature review focused on published articles that related to breast cancer, quality of life, body image, satisfaction, and BR. The EORTC QLQ-BRECON 23 is intended for use alongside the EORTC QLQ-C30 and BR23 to assess patient-reported outcomes in women undergoing mastectomy for invasive breast cancer or ductal carcinoma in situ.25 Content validity for this PROM showed sufficient high-quality evidence, with development phases incorporating literature reviews and interviews with patients and healthcare professionals.
Structural Validity

All three PROMs showed evidence of structural validity. Both BREAST-Q and EORTC QLQ-BRECON 23 were graded “high” for the quality of the evidence. Development of BREAST-Q involved Rasch modeling/methodology (a form of item response theory) to predict individual item responses and evaluate changes in an individual’s health-related quality of life (HRQL). Results showed that the fit to the Rasch model was good and item locations were spread out (0.7–6.6). EORTC QLQ-BRECON 23 used confirmatory factor analysis to test how well the measured variables represented the number of constructs. Studies included an adequate sample size in the analysis, and this instrument received an overall sufficient rating and high quality of evidence. BRECON-31 used exploratory factor analysis to identify the underlying relationships between the measured variables, however, the sample size included in the analysis was not adequate and scored overall an “insufficient” rating with low-quality evidence.

Internal Consistency

All three PROMs evaluated internal consistency, each scoring “high” for the quality of evidence. All questionnaires showed positive ratings, with Cronbach’s $\alpha$ scores ranging from 0.67 to 0.96, suggesting high interrelatedness among constituent outcome measure items. BREAST-Q studies reported acceptable Cronbach’s $\alpha$ values (of $\geq 0.70$) across the subscales (reconstruction module ranged from 0.88 to 0.96). There was an exception for surgical side effects within the EORTC QLQ-BRECON 23 questionnaire, which scored 0.67 for Cronbach’s $\alpha$, below the acceptable threshold for internal consistency.

Reliability

Reliability was assessed in all three PROMs. The quality of evidence for the measurement property varied, with only the BREAST-Q scoring as “high”-quality evidence. The intraclass correlation coefficient (ICC) was reported across all three PROMs. For BREAST-Q scale, reliability was supported by high Cronbach’s $\alpha$ values ($> 0.80$), high person separation indices ($\geq 0.73$), an ICC $> 0.80$, and appropriate item–total correlations (range of means 0.58–0.87). Test–retest reliability for all subscales of the BRECON-31 was good to excellent, with ICC showing excellent agreement (ICC $> 0.74$) for six of the subscales and good to fair agreement for self-image, arm, intimacy, and nipple subscales. For EORTC QLQ-BRECON 23, test–retest reliability was good, with ICCs for multiitem scales ranging from 0.809 to 0.916 and single items from 0.728 to 0.905. However, the quality of evidence scores for reliability for BRECON-31 and EORTC QLQ-BRECON 23 were “very low” and “moderate,” respectively.

Criterion Validity

Out of the three PROMs, only the BRECON-31 evaluated this measurement property. BRECON-31 used BREAST-Q as the reference standard (or gold standard) and performed well based on the level of concordance found between the two questionnaires. BRECON-31 showed excellent correlation (PCC $= 0.76$) for five of the subscales (satisfaction, self-conscious, arm concerns, appearance, and expectations).

Hypothesis Testing for Construct Validity

Hypothesis testing for construct validity was assessed across all three PROMs, evaluating and demonstrating positive supporting evidence. BREAST-Q was compared with EORTC QLQ-BRECON 23, and hypotheses relating to correlations between BREAST-Q scales and other scales were widely supported through moderate correlations. BRECON-31 was compared with EQ-5D results. The EQ-5D showed moderate agreement with a summary score of the BRECON-31 (PCC $= 0.50$, $p < 0.01$), and utility ratings correlated moderately with BRECON-31 (PCC $= 0.42$, $p < 0.001$). Construct validity for the EORTC QLQ-BRECON 23 questionnaire was assessed using exploratory factor analysis (EFA). The EFA supported the phase 3 provisional six scale structure; all item–factor weights exceeded 0.4.

Responsiveness

Of the three PROMs, only the EORTC QLQ-BRECON 23 evaluated this property. EORTC QLQ-BRECON 23 scored a sufficient overall rating and scored high for quality of evidence. Mean scale scores from baseline to 6 months were statistically significant ($p < 0.001$). For scales such as sexuality and surgical side effects, the effect sizes were small, 0.37 and 0.31, respectively.

Information on Feasibility of PROMs

Table 7 summarizes the different aspects of feasibility evaluated for each PROM. BREAST-Q and EORTC QLQ-BRECON 23 were reported to be acceptable, comprehensible, and easy to complete by patients. The three PROMs differed slightly in the amount of time these took for patients to complete, due to differing numbers of items per
| Relevant patient-reported outcome domains | Core outcome set (COS) item definition | Instruments evaluating patient-reported outcome domain in the RBS COS | Name of outcome measurement instrument(s) | Outcome/scales (number of items in scale in brackets) |
|-----------------------------------------|--------------------------------------|---------------------------------------------------------------|---------------------------------------------|---------------------------------------------------|
| Donor-site problems/morbidity           | Any problems or symptoms arising from the area from which the tissue was taken to reconstruct the breast, including hernias, stiffness, or numbness in the back, tummy, or bottom | BREAST Q: Abdominal appearance and function (13) Back appearance scale (8) Back and shoulder function scale (11) EORTC QLQ-BRECON 23: Donor-site symptoms (3) Surgical side effects (2) Satisfaction with donor scars (1) BRECON 31: Abdominal donor site (10) Electronic version of BREAST Q: Satisfaction with abdomen (3) | BREAST Q: | Abdominal appearance and function (13) Back appearance scale (8) Back and shoulder function scale (11) EORTC QLQ-BRECON 23: Donor-site symptoms (3) Surgical side effects (2) Satisfaction with donor scars (1) BRECON 31: Abdominal donor site (10) Electronic version of BREAST Q: Satisfaction with abdomen (3) |
| Self-esteem                             | Feeling self-confident               | BREAST Q: Single items in psychosocial wellbeing subscale: Confident in a social setting (1) Of equal worth to other women (1) Self-confident? (1) Like other women? (1) MBROS-BI: Mental health (5) BRECON 31: Self-image (4) Self-consciousness (3) I feel good about myself (1) | BREAST Q: | Single items in psychosocial wellbeing subscale: Confident in a social setting (1) Of equal worth to other women (1) Self-confident? (1) Like other women? (1) MBROS-BI: Mental health (5) BRECON 31: Self-image (4) Self-consciousness (3) I feel good about myself (1) |
| Emotional wellbeing                     | Feelings of emotional and psychological health after surgery | BREAST Q: Psychosocial wellbeing (10) Electronic version of BREAST Q: Psychosocial wellbeing (10) BRECON 31: Self-image: item “I feel good about myself” (1) MBROS BI: Role-emotional (3) Mental health (5) | BREAST Q: | Psychosocial wellbeing (10) Electronic version of BREAST Q: Psychosocial wellbeing (10) BRECON 31: Self-image: item “I feel good about myself” (1) MBROS BI: Role-emotional (3) Mental health (5) |
| Normality                                | Feeling “back to normal self” or “whole” as a result of surgery | BREAST Q: Satisfaction with breasts: How normal do you feel in your clothes? (1) Psychosocial wellbeing: Normal? (1) BRECON 31: Self-image: item “I feel normal” (1) MBROS BI: Body image: item “I feel whole” (1) | BREAST Q: | Satisfaction with breasts: How normal do you feel in your clothes? (1) Psychosocial wellbeing: Normal? (1) BRECON 31: Self-image: item “I feel normal” (1) MBROS BI: Body image: item “I feel whole” (1) |
| Quality of life                          | Women’s quality of life following surgery | BREAST Q: QoL domains: physical, psychosocial, and sexual wellbeing (32) Electronic version of BREAST Q: QoL domains: physical, psychosocial, and sexual wellbeing (32) BRECON 31: Recovery (4) EORTC QLQ-BRECON 23: HRQoL: before mastectomy and BR (4) HRQoL: relevant after BR (15) MBROS-BI: Functional wellbeing (7) Social wellbeing (7) | BREAST Q: | QoL domains: physical, psychosocial, and sexual wellbeing (32) Electronic version of BREAST Q: QoL domains: physical, psychosocial, and sexual wellbeing (32) BRECON 31: Recovery (4) EORTC QLQ-BRECON 23: HRQoL: before mastectomy and BR (4) HRQoL: relevant after BR (15) MBROS-BI: Functional wellbeing (7) Social wellbeing (7) |
| Physical well-being                     | Physical activity such as how well women can perform work- and leisure-related tasks after surgery | BREAST Q: Physical wellbeing: chest and upper body (16) Physical wellbeing: back and shoulder function scale (11) Electronic version of BREAST Q: Physical wellbeing (16) Physical wellbeing: abdomen (8) MBROS-BI: Vitality (4) BRECON 31: Arm concerns (4) “I have trouble moving my shoulder” (1) | BREAST Q: | Physical wellbeing: chest and upper body (16) Physical wellbeing: back and shoulder function scale (11) Electronic version of BREAST Q: Physical wellbeing (16) Physical wellbeing: abdomen (8) MBROS-BI: Vitality (4) BRECON 31: Arm concerns (4) “I have trouble moving my shoulder” (1) |
subscale. The EORTC QLQ-BRECON 23 had the longest completion time for patients; however, this is designed to be used alongside two other questionnaires: EORTC QLQ-30 (cancer) and QLQ-BR23 (breast cancer). Both BREAST-Q and BRECON-31 have been validated in BR patients; however, EORTC QLQ-BRECON 23 has only been validated in patients undergoing BR for cancer and has not been validated in a risk-reducing population.

DISCUSSION

This study is, to the best of the authors’ knowledge, the first to report a systematic review and critical appraisal of published studies reporting the measurement properties of PROMs developed for use in women undergoing BR using an updated COSMIN methodology. BR is performed to improve patients’ quality of life following mastectomy, and six key patient-reported outcome domains are included in the recently developed COS. It is vital that any PROM used to assess these important outcomes be robustly designed and validated if the results are to be meaningful. This review is the first necessary step to understand the performance of existing PROMs to inform instrument selection for patient-reported outcome domains in a BR CMS.

The systematic review identified 14 studies which included 6 different PROMs developed for use in a BR population. Of these, only three, BREAST-Q, BRECON-31, and EORTC QLQ-BRECON 23, were considered to have adequate content validity and were eligible for full measurement property assessment. All three instruments have been used to assess patient-reported outcomes in BR studies, but the most widely used and cited is BREAST-Q.

BREAST-Q, BRECON-31, and EORTC QLQ-BRECON 26 all had thorough patient involvement in item generation and reduction, which has shown to be critical and to greatly increase the validity of BR PROMs.

Strengths and Limitations

This study has certain strengths and limitations. To the best of the authors’ knowledge, this is the first study that has used the recently updated COSMIN guidelines to assess the methodological quality of validation studies of BR PROMs. A validated and highly sensitive search strategy using published guidance from Terwee et al. was used to identify all potentially relevant studies, and three independent reviewers independently assessed the quality of each study (any disagreements resolved by a fourth reviewer), as recommended by COSMIN. The main limitation to this review is the assumption that, if validation studies of BR PROMs were not identified from the search, these had not been carried out. Therefore, the possibility of publication bias cannot be excluded. In addition, this review focused on PROMs developed in a BR population. However, there may be other instruments that may have value in this group (e.g., measures of self-esteem) but were not considered as these had not been developed or validated specifically in BR patients.

| Relevant patient-reported outcome domains | Core outcome set (COS) item definition | Instruments evaluating patient-reported outcome domain in the RBS COS |
|------------------------------------------|--------------------------------------|------------------------------------------------------------------|
| Women’s cosmetic satisfaction             | Women’s overall satisfaction with the appearance of their reconstructed breast(s) after surgery | BREAST Q: Satisfaction with breasts (15) Satisfaction with implants (2) Satisfaction with nipple reconstruction (1) BREAST Q CAT: Satisfaction with breasts (10) Electronic version of BREAST Q: Satisfaction with breast (16) Satisfaction with outcome (7) BRECON 31: Satisfaction (4) EORTC QLQ-BRECON 23: Satisfaction with breast cosmesis (6) Satisfaction with nipple cosmesis (2) Satisfaction with surgery (3) MBROS-Satisfaction(S): General satisfaction with reconstruction (5) Aesthetic satisfaction: breast size/shape/firmness (2) MBROS-Body image (BI): Patient perceptions of physical appearance after BR (9) Subjective rating scale for BR: The overall appearance of the breast (1) |
| Author/ year | Country of study/setting | Instrument name | Sample size | Age: mean (SD/range) | Population | Type of BR | Indication for surgery |
|-------------|--------------------------|----------------|-------------|----------------------|------------|------------|------------------------|
| Pusic et al.19 | N. America, Canada | BREAST Q | 1950 (presurgery = 908, postsurgery = 1807) | Presurgery 43 (14/18–84), Postsurgery 47 (12/18–84) | Pre-op and post-op breast surgery patients recruited from five centers in the USA and Canada | Breast surgery | Breast surgery |
| Cano et al.20 | North America | BREAST Q | 817 | 49 (12/20–82) | Breast surgery patients (pre- and post-operative > 18 years) | NR | Breast surgery |
| Browne et al.21 | UK | BREAST Q (2 novel scales: back appearance scale and back and shoulder function scale) | 1096 | Median age = 52 (range 18–50) | Breast cancer patients having latissimus dorsi BR after mastectomy | Latissimus dorsi BR | Breast cancer |
| Young-Afat et al.31 | North America | BREAST Q computerized adaptive testing (CAT) | 5000 | NR (women were 22 years and older) | Women who had undergone implant-based BR randomly selected from 17,000 who had completed the satisfaction-with-breast scale | Implant based BR | Breast cancer |
| Fuzesi et al.32 | North America | Electronic version of BREAST Q | 1956 (completed BR module) | 55 (9.3) | Women with history of BCa completing online survey | Breast surgery | Breast surgery |
| Temple et al.22 | Canada | BRECON-31 | 20 (women participating in focus groups) | 54 (range 36–69) | Women who had previously undergone BR | 16 autologous and 11 alloplastic BR (13 were unilateral & 11 bilateral) | Breast surgery |
| Temple-Oberle et al.23 | Canada | BRECON-31 | 128 | 52.7 | Women who had previously undergone BR | Combination of an autologous and alloplastic BR | Diagnosed with invasive mammary carcinoma, ductal carcinoma in situ, BRCA-associated or another breast disease |
| Temple-Oberle et al.24 | Canada | BRECON-31 | 50 | 49.1 (7.6) | Consecutive women presenting for final F/up who had completed BR | Bilateral BR | NR |
| Thomson et al.25 | UK, Italy, Sweden | EORTC QLQ-BRECON | 31 (semi structured interviews) | 50 (range 33–66) | LD, TRAM/DIEP, and implant-based BR techniques after mastectomy for BCa | LD, TRAM/DIEAP, and implant-based BR techniques | For women undergoing mastectomy for invasive BCa, ductal carcinoma in situ, or prophylactic surgery |
| Winters et al.26 | UK, Austria, Belgium, Italy, and Sweden | EORTC QLQ-(BRR) BRECON 26 | 150 (retrospective group post BR) | NR | 1–5 years after immediate or delayed BR | Mastectomy BR implant only, pedicle LD with implant, autologous LD, and microvascular free abdominal flaps such as TRAM and DIEP | Diagnosed with BCa or ductal carcinoma in situ requiring mastectomy and BR |
| Author/ Year | Country of study/setting | Instrument name | Sample size | Age: mean (SD/range) | Population | Type of BR | Indication for surgery |
|-------------|--------------------------|----------------|-------------|---------------------|------------|------------|------------------------|
| Winters et al.27 | 28 international centers | EORTC QLQ-BRECON 23 | 438 (234 in prospective cohort and 204 in cross-sectional cohort). Implants (176), donor-size flaps (166) | 50.7 (27–78) | Patients with breast cancer undergoing mastectomy and BR | Mastectomy and BR (implant and autologous BR) | Breast cancer or ductal carcinoma in situ |
| Alderman et al. 2000 | USA and Canada | MBROS-S | 212 | Implant patients = 48.5 Pedicle TRAM flap = 49.4 Free TRAM flap = 46.4 | Mastectomy reconstruction patients: Women who had undergone first time immediate or delayed BR surgery | Expander/implant Pedicle TRAM flap Free TRAM flap | Women who had undergone first time immediate or delayed BR surgery |
| Wilkins et al. 29 | USA and Canada | MBROS-BI | 273 | Implant patients = 48.5 Pedicle TRAM flap = 49.4 Free TRAM flap = 46.4 | Mastectomy reconstruction patients: Women who had undergone first time immediate or delayed BR surgery | Tissue expander/implant Pedicle TRAM flap Free TRAM flap | Patients undergoing immediate or delayed postmastectomy BR |
| Cohen et al. 30 | USA | Patient-based subjective rating scale for BR appearance | 36 | NR | Patients photographs (frontal and lateral views) taken as part of their routine post-op visits after BR | Autologous BR (transverse rectus abdominis myocutaneous flap BR) | NR |

NA not available, NR not reported, BR breast reconstruction, BCa breast cancer, TRAM transverse rectus abdominis myocutaneous flap, DIEP deep inferior epigastric artery perforator flap, LD latissimus dorsi flap, F/up follow-up, USA United States; EORTC QLQ-BR26 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 26-item breast reconstruction module, MBROS-S Michigan Breast Reconstruction Outcome study-satisfaction questionnaire, MBROS-BI Michigan Breast Reconstruction Outcome study-body image questionnaire, CAT computerized adaptive testing
| COSMIN Measurement property | BREAST Q | | BRECON 31 | | EORTC QLQ-BRECON 23 | |
|----------------------------|----------|----------------------------|----------------|-----------------|--|--|
| **Content validity**       |          |                            |                |                 |                |
| Relevance                  | Sufficient (+) | High                     | Sufficient (+) | High            | Content validity: (+) | Sufficient (+) | High |
| Comprehensiveness           | Sufficient (+) | High                     | Sufficient (+) | High            | Comprehensiveness: | Sufficient (+) | High |
| Comprehensibility           | Sufficient (+) | High                     | Sufficient (+) | High            | Comprehensibility: | Sufficient (+) | High |
| **Structural validity**     | Pusic 2009 (+) | High                     | Used EFA to assess structural validity | Insufficient (-) | Low | Winters 2014 (?) | Insufficient (?) | High |
|                            | Cano 2012 (+) | High                     | Fit to Rasch model was good | Sufficient (+) | High | Winters 2018 (?) | Sufficient (+) | High |
| **Internal consistency**    | Pusic 2009 (+) | High                     | Temple-Oberle 2012 (?), Cronbach’s α ranged from 0.67 to 0.91 | Indeterminate (?) | High | Winters 2014 (+) | Sufficient (+) | High |
|                            | Cano 2012 (+) | High                     | Temple-Oberle 2013 (?), Cronbach’s α range from 0.34 to 0.92 | Sufficient (+) | High | Winters 2018 (+) | Sufficient (+) | High |
|                            | Cronbach’s α: 0.81–0.96 | Sufficient (+) |              |                  |                | Winters 2014 (+) | Sufficient (+) | High |
|                            | Cronbach’s α: > 0.80 | Sufficient (+) |              |                  |                | Winters 2018 (+) | Sufficient (+) | High |
| **Cross-cultural validity/ measurement invariance** | No information available | N/A | No information available | N/A | No information available | N/A | N/A | No information available | N/A | N/A |
| **Reliability**             | Pusic 2009 (+) | High                     | Temple-Oberle 2012 (+), ICC > 0.74 | Insufficient (-) | Very low | Winters 2014 (NA) | Sufficient (+) | Moderate |
|                            | Cano 2012 (+) | High                     | Temple-Oberle 2013 (NA) | Sufficient (+) | High | Winters 2018 (+) | Sufficient (+) | Moderate |
|                            | ICC > 0.70 | Sufficient (+) |               |                  |                | Test-retest reliability was good with ICCs for multi item scales ranging from 0.809 to 0.916 and single items from 0.728 to 0.905 | Sufficient (+) | Moderate |
|                            | ICC > 0.80 | Sufficient (+) |               |                  |                |                           | Sufficient (+) | Moderate |
| **Measurement error**       | No test for measurement error | N/A | No test for measurement error | N/A | No test for measurement error | N/A | N/A | N/A | N/A |
| **Criterion validity**      | No information available | N/A | Temple-Oberle 2012 | Sufficient (+) | High | No information available | N/A | N/A |
|                            |              |                           | Excellent correlation with gold standard (Breast-Q) for satisfaction subscales (PCC = 0.76) |              |                |                              | N/A | N/A |
| **Hypothesis testing (for construct validity)** | The result was in accordance with the hypothesis | Sufficient (+) | The result was in accordance with the hypothesis | Sufficient (+) | Moderate | The result was in accordance with the hypothesis | Sufficient (+) | High |
| **Responsiveness**          | No information available | N/A | No information available | N/A | No information available | N/A | N/A | The result was in accordance with the hypothesis | Sufficient (+) | High |

N/A not applicable
+ sufficient, — insufficient, ? indeterminate
Critical appraisal was undertaken using the COSMIN checklist. This methodology has recently been developed and requires that PROM developers report in detail the methods used in the development and validation of their instrument. For PROMs developed before the introduction of COSMIN guidance, this information is often not reported in sufficient detail, if at all, and sometimes assumptions need to be made based on the information the author(s) have provided. Researchers developing PROMs in the future will need to follow COSMIN recommendations when reporting their studies to ensure complete reporting of study details and accurate interpretation of results.

**Further Work**

The aim of this review was to identify robustly validated PROMs that could be recommended to measure the six key patient-reported outcome domains in the BR COS. The three PROMs identified in this review measure most of the key constructs with specific subscales that adequately address each domain. The domains of “normality” and “self-esteem,” however, are not constructs specifically included in any of the identified instruments, but both BREAST-Q and BRECON-31 include single items which reflect these domains. Further work is now required to determine whether patients feel that these items are adequate or whether work is needed to develop new PROMs in these areas.

Next steps will involve consensus work with key stakeholders to determine which of the three candidate PROMs should be recommended for use. This process involving a modified Delphi survey with over 100 professional stakeholders and face-to-face consensus meetings is already underway. Qualitative work with patients who have undergone BR surgery will also be needed to ensure that the selected PROMs are acceptable for this group.

**CONCLUSIONS**

This systematic review identified three robustly developed and validated PROMs that could be recommended for use in future BR studies and inclusion in the CMS. Work is now required to determine which instrument should be routinely recommended for use to improve the quality and comparability of BR research and optimize its value for patients.
| Feasibility aspects | BREAST Q | BRECON 31 | EORTC QLQ-BRECON 23 |
|---------------------|----------|-----------|---------------------|
| **Patient comprehensibility** | Patients found questionnaire to be acceptable, comprehensive, and clear | Not stated | Found to be acceptable for the majority of women and was quick and easy to complete |
| **Domains/subscales and number of items (core outcomes are highlighted in bold)** | | | |
| Six subscales | | | |
| **Satisfaction with breasts (15 items)** | | | |
| Satisfaction with overall outcome (7 items) | | | |
| Satisfaction with information/care (15 items) | | | |
| **Psychosocial wellbeing (10 items)** | | | |
| Sexual wellbeing (6 items) | | | |
| **Physical wellbeing (chest and upper body) (11 items)** | | | |
| Total 69 items | | | |
| | | | |
| **Completion time** | Reconstruction module only: 10–15 min | 5 min | 20–30 min |
| **Patient’s required mental and physical ability level** | All content was targeted to sixth-grade reading level | The final items were refined for sixth-grade reading level according to Flesch-Kincaid, language and spelling according to Merriam-Webster online dictionary | |
| | | | |
| **Ease of standardization** | The BREAST Q scales are not considered valid for patient groups that were not represented in the development process | | |
| **Ease of score calculation** | Acceptable | Easy scoring | Easy scoring |
| **Copyright** | Memorial Sloan Kettering Cancer Centre and Uni of British Columbia 2007 | 2012 Wiley Periodicals, Inc | EORTC |
| **Cost of an instrument** | No fee for use by academics | Not stated | No fee for use by academics |
| **Required equipment** | None | None | None |
| **Regulatory agency’s requirement for approval** | Local institutional ethics review board approval was obtained for 3 centers in the USA and Canada | Approved by the institutional review board of the University of Western Ontario | Ethical approval from the National Research Ethics Committee Northampton |
| **No. of studies citing/using instrument questionnaire** | 478 | 8 | 5 |
| **Other considerations** | Validated in breast reconstruction patients | Validated in breast reconstruction patients | Only validated in patients undergoing breast reconstruction for cancer (not validated in risk-reducing population) |

*As cited in Web of Science August 2019*
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**AUTHOR CONTRIBUTIONS** S.P. and J.M.B. conceived the study. S.P. and C.D. performed the searches and abstract screening. C.D. performed the data extraction. C.D., K.A., R.M., and S.P. were involved in the COSMIN evaluation. C.D. wrote the first draft of the manuscript. All authors critically reviewed the manuscript and approved the final version prior to submission.

**FUNDING** This work is funded by a National Institute for Health Research Clinician Scientist Award (CS-2016-16-019) to S.P. K.A. and R.M. are funded/supported by the NIHR Biomedical Research Centre (BRC) at University Hospitals Bristol NHS Foundation Trust and the University of Bristol and infrastructure support from the Royal College of Surgeons of England Bristol Surgical Trials Centre. J.M.B. is an NIHR Senior Investigator. The views and opinions expressed are those of the authors and do not necessarily reflect those of the National Institute for Health Research, the National Health Service, or the Department of Health and Social Care.

**APPENDIX: SEARCH STRATEGY FOR THE SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT REPORTED OUTCOME MEASURES IN RECONSTRUCTIVE BREAST SURGERY**

“Breast”

1. Breast/
2. Breast.mp
3. OR/14-15
4. Limit 16 to English, humans

AND

“Reconstruction”

1. Reconstructive Surgical Procedures/
2. Surgical Flaps/
3. Surgery, Plastic/
4. Breast Implants/
5. Prostheses and implants/
6. Tissue Expansion Devices/
7. Reconstruct$.mp
8. Expan$.mp
9. Implant$.mp
10. Prosthе$.mp
11. Flap$.mp
12. Latissimus.mp
13. LD.mp
14. TRAM.mp
15. DIEP.mp
16. Plastic surg$.mp
17. Myocutaneous.mp
18. Myofascial.mp
19. Musculocutaneous.mp
20. Thoracodorsal.mp
21. TUG.mp
22. SGAP.mp
23. acellular dermal matri$.mp
24. mesh.mp
25. Strattice.mp
26. Surgimend.mp
27. AlloDerm.mp
28. BRAXON.mp
29. TiLOOP.mp
30. OR/1-29
31. Limit 30 (English, humans),

AND

COSMIN Measurement properties\(^1\) filter

1. (instrumentation or methods).sh.
2. (Validation Studies or Comparative Study).pt.
3. exp Psychometrics/
4. psychometr*.ti,ab.
5. (clinimetr* or clinometr*).tw.
6. exp “Outcome Assessment (Health Care)”/
7. outcome assessment.ti,ab.
8. outcome measure*.tw.
9. exp Observer Variation/
10. observer variation.ti,ab.
11. exp Health Status Indicators/
12. exp “Reproducibility of Results”/
13. reproduceb*.ti,ab.
14. exp Discriminant Analysis/
15. (reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or “internal consistency”).ti,ab.
16. (cronbach* and (alpha or alphas)).ti,ab.
17. (item and (correlation* or selection* or reduction*)).ti,ab.
18. (agreement or precision or imprecision or “precise values” or test-retest).ti,ab.
19. (test and retest).ti,ab.
20. (reliab* and (test or retest)).ti,ab.

\(^1\) Terwee CB, Jansma EP, Riphagen II, Vet HCW. Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. *Qual Life Res.* 2009;18(8):1115–1123.
5. ((patient or self or child or parent or carer or proxy) adj health status.mp.
6. (disability or function or functional or functions or subjective or utility or utilities or wellbeing or well being) adj2 (index or indices or instrument or instruments or measure or measures or questionnaire* or profile or profiles or scale or scales or score or scores or status or survey or surveys)).ti,ab.
7. OR/ 1-6
8. Limit 7 to English
Combine searches with AND.

REFERENCES

1. Brewster A, Helzlssouer K. Breast cancer epidemiology, prevention and early detection. Curr Opin Oncol. 2001;13:420–5.
2. www.breastcancercare.org.uk (accessed July 2019).
3. Harcourt D, Rumsey N. Psychological aspects of breast reconstruction: a review of the literature. J Adv Nurs. 2001;35(4):477–87.
4. Potter S, Harcourt D, Cawthorn S, et al. Assessment of cosmesis after breast reconstruction surgery: a systematic review. Ann Surg Oncol. 2011;18(3):813–23.
5. Potter S, Brigic A, Whiting PF, et al. Reporting clinical outcomes of breast reconstruction: a systematic review. J Natl Cancer Inst. 2011;103(1):31–46.
6. Potter S, Holcombe C, Ward JA, Blazebey JM. Development of a core outcome set for research and audit studies in reconstructive breast surgery. Br J Surg. 2015;102(11):1360–71.
7. Prinsen CA, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set’. Trials. 2014;15:247.
8. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745–53.
9. Schmitt J, Apfelbacher C, Spuls PI, et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2014;135(1):24–30.
10. Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1171–9.
11. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–57.
12. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651–7.
13. Patient Reported Outcomes Measurement Group. University of Oxford http://phi.ueh.ox.ac.uk (accessed Feb 2019).
14. Terwee CB, Jansma EP, Riphagen, II, de Vet HC. Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res. 2009;18(8):1115–23.
15. Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, De Vet HCW, Terwee CB. COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs). User Manual Version 1 Feb 2018. 2018.
16. Terwee CB, Prinsen CA, Chiarotto A, et al. COSMIN standards and criteria for evaluating the content validity of health-related
Patient-reported outcome measures: a Delphi study. *Qual Life Res.* 2018;27(5):1159–70.

17. Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. *Qual Life Res.* 2018;27(5):1159–70.

18. GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013.

19. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. *Plast Reconstr Surg.* 2009;124(2):345–53.

20. Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. *Plast Reconstr Surg.* 2012;129(2):293–302.

21. Browne JP, Jeevan R, Pusic AL, et al. Measuring the patient perspective on latissimus dorsi donor site outcomes following breast reconstruction. *J Plast Reconstr Aesthet Surg.* 2018;71(3):336–43.

22. Temple CL, Cook EF, Ross DC, Bettger-Hahn M, MacDermid J. Development of a breast reconstruction satisfaction questionnaire (BRECON): dimensionality and clinical importance of breast symptoms, donor site issues, patient expectations, and relationships. *J Surg Oncol.* 2010;101(3):209–16.

23. Temple-Oberle CF, Cook EF, Bettger-Hahn M, Mychailyshyn N, Naeem H, MacDermid J. Development of a breast reconstruction satisfaction questionnaire (BRECON-31): principal components analysis and clinimetric properties. *J Surg Oncol.* 2012;106(7):799–806.

24. Temple-Oberle CF, Ayeni O, Cook EF, Bettger-Hahn M, Mychailyshyn N, MacDermid J. The breast reconstruction satisfaction questionnaire (BRECON-31): an affirmative analysis. *J Surg Oncol.* 2013;107(5):451–5.

25. Thomson HJ, Winters ZE, Brandberg Y, Didier F, Blazeby JM, Mills J. The early development phases of a European Organisation for Research and Treatment of Cancer (EORTC) module to assess patient reported outcomes (PROs) in women undergoing breast reconstruction. *Eur J Cancer (Oxford, England : 1990).* 2013;49(5):1018–26.

26. Winters ZE, Balta V, Thomson HJ, et al. Phase III development of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire module for women undergoing breast reconstruction. *Br J Surg.* 2014;101(4):371–82.

27. Winters ZE, Afzal M, Rutherford C, et al. International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction. *Br J Surg.* 2018;105(3):209–22.

28. Alderman AK, Wilkins EG, Lowery JC, Kim M, Davis JA. Determinants of patient satisfaction in postmastectomy breast reconstruction. *Plast Reconstr Surg.* 2000;106(4):769–76.

29. Wilkins EG, Cederna PS, Lowery JC, et al. Prospective analysis of psychosocial outcomes in breast reconstruction: one-year postoperative results from the Michigan Breast Reconstruction Outcome Study. *Plast Reconstr Surg.* 2000;106(5):1014–25 (discussion 1026–1017).

30. Cohen M, Evanoff B, George LT, Brandt KE. A subjective rating scale for evaluating the appearance outcome of autologous breast reconstruction. *Plast Reconstr Surg.* 2005;116(2):440–9.

31. Young-Afat DA, Gibbons C, Klassen AF, Vickers AJ, Cano SJ, Pusic AL. Introducing BREAST-Q computerized adaptive testing: short and individualized patient-reported outcome assessment following reconstructive breast surgery. *Plast Reconstr Surg.* 2019;143(3):679–84.

32. Fuzesi S, Cano SJ, Klassen AF, Atisha D, Pusic AL. Validation of the electronic version of the BREAST-Q in the army of women study. *Breast (Edinburgh, Scotland).* 2017;33:44–9.

33. Liu LQ, Branford OA, Mehigan S. BREAST-Q measurement of the patient perspective in oncoplasty breast surgery: a systematic review. *Plast Reconstr Surg.* 2018;140(2):e1904.

34. Potter S, Davies C, Holcombe C, et al. International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol. *BMJ.* 2020;10(1):e035505.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.